-
公开(公告)号：US20220135959A1
公开(公告)日：2022-05-05
申请号：US17496092
申请日：2021-10-07
Applicant: Bioverativ Therapeutics Inc.
Inventor： Joe SALAS , Elena KISTANOVA , Vu Phong HONG , Adam R. MEZO , Robert T. PETERS
Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
-
公开(公告)号：US20210355473A1
公开(公告)日：2021-11-18
申请号：US17222636
申请日：2021-04-05
Applicant: Bioverativ Therapeutics Inc.
Inventor： Joe SALAS , Robert PETERS , Alan BITONTI
IPC: C12N9/64 , C07K14/745 , C07K16/28 , C07K14/755 , C12N9/96 , C07K16/18
Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.
-
Patent Agency Ranking
公开(公告)号：US20210292729A1
公开(公告)日：2021-09-23
申请号：US17152470
申请日：2021-01-19
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Joe SALAS , Robert T. PETERS
IPC: C12N9/64 , C07K14/745 , C07K16/28 , C07K14/755 , C12N9/96 , C07K16/18
Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.
-
公开(公告)号：US20190225957A1
公开(公告)日：2019-07-25
申请号：US16228144
申请日：2018-12-20
Applicant: Bioverativ Therapeutics Inc.
Inventor： Joe SALAS , Elena KISTANOVA , Vu Phong HONG , Adam R. MEZO , Robert T. PETERS
Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.
-
公开(公告)号：US20220243189A1
公开(公告)日：2022-08-04
申请号：US17577684
申请日：2022-01-18
Applicant: Bioverativ Therapeutics Inc.
Inventor： Vu Phong HONG , Adam R. MEZO , Joe SALAS , Robert PETERS
Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
-
公开(公告)号：US20220233650A1
公开(公告)日：2022-07-28
申请号：US17618808
申请日：2020-06-18
Applicant: BIOVERATIV THERAPEUTICS INC.
Inventor： Susu DUAN , Katalin KIS-TOTH , Gaurav Manohar RAJANI , Joe SALAS
Abstract: Disclosed herein are methods of treating subjects with hemophilia and low bone mineral density (BMD) with a chimeric protein comprising a coagulation factor and a Fc domain. In certain embodiments, the chimeric protein is rFVIIIFc. In certain embodiments, a subject to be treated has hemophilia A.
-
公开(公告)号：US20190309280A1
公开(公告)日：2019-10-10
申请号：US16357153
申请日：2019-03-18
Applicant: Bioverativ Therapeutics Inc.
Inventor： Vu Phong HONG , Adam R. MEZO , Joe SALAS , Robert PETERS
Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disefficacy orders using the disclosed compounds, methods of enhancing in vivo of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
